Pregnancy blood tests and prenatal urine tests are used for several different purposes. Early testing commonly evaluates pregnancy hormone status when needed, blood counts, blood type and Rh factor, unexpected red-cell antibodies, urine bacteria, immunity to selected infections, and infections that can affect the pregnant patient or newborn. Later testing may include gestational diabetes screening, repeat blood counts or antibody testing, risk-based repeat infection testing, and group B streptococcus screening. Thyroid, iron, kidney, liver, or other tests are added when history, symptoms, medication use, or prior results support them.
The exact schedule is not identical for every pregnancy. Prenatal clinicians adjust testing for gestational age, multiple pregnancy, prior complications, chronic conditions, local public-health requirements, new exposures, and results already documented in the medical record. Direct-access testing may supply selected data, but it cannot safely design or replace that coordinated schedule.
Direct-access laboratory testing does not replace prenatal care. Pregnancy testing often depends on gestational age, symptoms, ultrasound findings, blood pressure, prior results, medications, and the care plan established by an obstetric clinician. Severe bleeding, severe abdominal or pelvic pain, fainting, severe headache, vision changes, chest pain, shortness of breath, fluid leakage, reduced fetal movement, or another urgent pregnancy concern requires immediate medical care rather than routine self-ordered testing.20
Blood and urine testing by stage of pregnancy, including hCG, blood type and Rh factor, antibody screening, CBC, infection testing, gestational diabetes screening, thyroid tests, iron studies, and prenatal genetic screening.
Ultrasound, examination, blood-pressure measurement, fetal monitoring, genetic counseling, and diagnostic procedures answer questions that routine blood and urine tests cannot.
This timeline describes common testing windows, not a personalized prenatal schedule. A prenatal clinician may move, repeat, omit, or add tests based on the individual pregnancy.
| Stage | Common laboratory questions | Examples of tests commonly discussed | What requires prenatal-clinician coordination |
|---|---|---|---|
| Before pregnancy | Is there a known anemia, immunity gap, chronic condition, infection risk, or inherited-disease risk that should be addressed before conception? | CBC; ferritin or iron studies when indicated; rubella or varicella immunity if records are uncertain; diabetes or thyroid testing based on history; infection and carrier screening based on guidelines and risk | Vaccine timing; medication changes; treatment of infection; genetic counseling; management of diabetes, thyroid disease, anemia, kidney disease, or other chronic conditions |
| Pregnancy confirmation and first prenatal evaluation | Is pregnancy confirmed when testing is needed? What are the patient’s blood type, Rh status, blood counts, antibody status, infection status, and urine-culture result? | Qualitative hCG or quantitative hCG for a defined question; CBC; ABO/Rh; RBC antibody screen; urinalysis; urine culture; rubella IgG; HBsAg; hepatitis C testing; HIV; syphilis; varicella immunity when appropriate; age- and risk-based chlamydia/gonorrhea; hemoglobinopathy testing if no prior result | Dating and viability assessment; ultrasound; evaluation of pain or bleeding; interpretation of positive infection tests; positive antibody management; Rh immune globulin decisions; carrier-screening plan |
| About 10 weeks and later | Is prenatal chromosome screening desired after informed counseling? | Cell-free DNA screening may be available from about 10 weeks; other first-trimester screening pathways may combine blood tests and ultrasound | Selection of one screening strategy; pretest counseling; ultrasound coordination; follow-up of positive, negative, or nonreportable results |
| First trimester diagnostic window | Is definitive fetal genetic information needed because of preference, family history, ultrasound findings, or a screening result? | Chorionic villus sampling uses placental tissue rather than a routine blood draw | CVS is an invasive diagnostic procedure and must be arranged through an experienced prenatal team, usually with genetic counseling |
| Second trimester screening window | Is screening for neural-tube defects or selected chromosome conditions desired or still needed? | Maternal serum AFP, triple screen, or quad screen depending on the selected pathway; AFP is commonly performed around 15 to 20 weeks | Correct gestational dating, interpretation, ultrasound correlation, and follow-up of an abnormal result |
| About 24 to 28 weeks | Is gestational diabetes present? Has anemia developed or worsened? | Glucose challenge and, when indicated, diagnostic oral glucose tolerance testing; repeat CBC according to the prenatal plan | Choice of one-step or two-step glucose pathway; fasting instructions; diagnosis; nutrition and medication management |
| Around 28 weeks when relevant | Has an Rh-negative patient developed antibodies, and is Rh immune globulin indicated? | Repeat antibody screen may be used in the prenatal plan | Rh immune globulin, interpretation after prophylaxis, sensitization management, bleeding or procedure-related decisions |
| Third trimester | Has infection risk changed? Are repeat tests required by the clinical plan, state law, local epidemiology, or prior results? | Repeat syphilis testing; HIV, chlamydia, gonorrhea, hepatitis B, or other testing when indicated; repeat CBC or targeted chemistry tests when clinically needed | Treatment, partner management, fetal or newborn planning, and timing around delivery |
| About 36 to 37 weeks | Is group B streptococcus present in the vagina or rectum close to delivery? | Vaginal-rectal GBS culture | Correct specimen collection, documentation, and intrapartum antibiotic plan; this is not replaced by an earlier urine culture |
| Labor, delivery, or urgent presentation | Are critical prenatal results missing, or is an acute complication suspected? | Rapid HIV testing if status is unknown; infection, blood count, chemistry, coagulation, urine, or other tests selected for the situation | Immediate obstetric assessment, fetal monitoring, imaging, treatment, transfusion planning, and newborn prophylaxis |
| Test or procedure | Category | What it asks | What a result means | Oversight needed |
|---|---|---|---|---|
| CBC, infection tests, urine culture, glucose screening | Maternal screening | Is there a maternal condition or exposure that may affect pregnancy care? | A screening result may be normal, abnormal, or require confirmation; it does not evaluate fetal anatomy | Ordered and interpreted within prenatal care, especially when positive or time-sensitive |
| Carrier screening | Reproductive genetic screening | Does a parent carry a gene variant that could be inherited? | A carrier result does not mean the parent has an affected fetus; partner testing and residual-risk counseling may be needed | Pretest and post-test counseling; partner and fetal-testing decisions |
| Cell-free DNA or NIPS | Fetal chromosome screening | Is the probability of selected chromosome conditions increased? | High-risk, low-risk, or nonreportable results are probabilities, not diagnoses | Prenatal clinician or genetics professional should select the test and manage follow-up; positive results require diagnostic confirmation before irreversible decisions1112 |
| First-trimester or second-trimester serum screening | Fetal risk screening | Is the calculated chance of selected chromosome or structural conditions increased? | Risk estimate depends on gestational age and other clinical data; abnormal results need counseling and follow-up | Correct timing, dating, and integration with ultrasound and prior screening |
| Maternal serum AFP | Neural-tube and selected condition screening | Is AFP higher or lower than expected for the pregnancy context? | It does not diagnose a fetal condition; dating, multiples, maternal factors, ultrasound, and additional testing matter14 | Prenatal interpretation and follow-up |
| Chorionic villus sampling | Diagnostic procedure | Do sampled placental cells show a chromosome or genetic condition being evaluated? | Provides diagnostic information for the tested condition, but has procedural limitations and risks | Maternal-fetal medicine, obstetric, and genetics oversight |
| Amniocentesis | Diagnostic procedure | Do sampled amniotic-fluid cells or analytes show a condition being evaluated? | Provides diagnostic information for the tested condition, but has procedural limitations and risks | Maternal-fetal medicine, obstetric, and genetics oversight |
ACOG recommends that prenatal genetic screening and diagnostic-testing options be discussed and offered to all pregnant patients, while respecting the patient’s choice to accept or decline testing.10 Choosing among these options is not simply a matter of ordering the largest panel. The decision should account for gestational age, what conditions the test covers, prior screening, ultrasound findings, personal values, and how the patient would use the information.
Human chorionic gonadotropin, or hCG, is produced during pregnancy. A qualitative hCG test reports whether hCG is detected. A quantitative hCG test reports a numerical concentration.3
A single quantitative result generally cannot prove that the pregnancy is viable, locate the pregnancy, establish exact gestational age, or exclude ectopic pregnancy. Results overlap widely among normal and abnormal pregnancies. When pain, bleeding, uncertain dating, or another concern exists, the prenatal team may use serial hCG measurements together with transvaginal ultrasound and clinical assessment.
Do not delay urgent evaluation to obtain a self-ordered hCG level when there is severe pelvic or abdominal pain, shoulder pain, heavy bleeding, dizziness, or fainting.
Three related results answer different questions:
| Result | What it tells the prenatal team | What it does not tell the team |
|---|---|---|
| ABO group | Whether the patient is type A, B, AB, or O | It does not determine whether fetal red cells are at risk from a maternal antibody |
| Rh D type | Whether the patient is Rh positive or Rh negative | Rh-negative status alone does not mean sensitization has occurred |
| RBC antibody screen | Whether unexpected antibodies against red-cell antigens are detectable | A positive screen does not identify the antibody until additional testing is performed |
The antibody screen is usually performed early in pregnancy. Clinically important antibodies may include anti-D and antibodies to other antigens, such as Kell. If the screen is positive, the laboratory may perform antibody identification, and the prenatal team may add titers, paternal or fetal antigen assessment, or specialized fetal surveillance depending on the antibody.15
For an Rh-negative patient who is not already sensitized, the prenatal team may recommend Rh(D) immune globulin at a routine antepartum point and after specific events such as bleeding, trauma, procedures, pregnancy loss, or delivery of an Rh-positive infant. The regimen and timing must be managed clinically. Rh immune globulin can also affect later antibody-screen interpretation, so the laboratory and clinician need the administration history.16
A direct-access ABO/Rh or antibody result cannot replace the action plan that follows. A positive antibody screen, an Rh-negative result with bleeding, or uncertainty about prior Rh immune globulin requires prompt prenatal follow-up.
For a broader explanation of CBC patterns, hemoglobin, red-cell indices, ferritin, iron studies, vitamin B12, and folate, see the anemia and blood-count testing guide.
A pregnancy CBC measures red cells, hemoglobin, hematocrit, red-cell indices, white cells, and platelets. It can help identify anemia, macrocytosis or microcytosis, low platelets, and other patterns that warrant follow-up.
Pregnancy expands plasma volume, so hemoglobin and hematocrit often decrease even when red-cell mass increases. White blood cell counts may rise physiologically, and platelet counts may shift. These changes make pregnancy-specific interpretation important. A flagged result based on a nonpregnant reference range may not represent disease, while a result technically inside a broad adult range may still matter in pregnancy.
Ferritin and iron studies are not interchangeable with a CBC. Ferritin reflects stored iron but can rise with inflammation or illness. Serum iron varies with timing, meals, and supplements. When anemia, low mean corpuscular volume, diet, symptoms, blood loss, or a prior history raises concern, a prenatal clinician may use ferritin and other iron measures to distinguish iron deficiency from hemoglobinopathy or another cause.
The USPSTF concluded in 2024 that evidence is insufficient to determine the balance of benefits and harms of routine screening or routine supplementation specifically for iron deficiency with or without anemia in asymptomatic pregnant patients. Other organizations and clinical practices vary, so testing decisions should be individualized rather than assumed to be universal.17
Urinalysis and urine culture answer different questions.
The USPSTF recommends a midstream, clean-catch urine culture at the first prenatal visit or at 12 to 16 weeks, whichever is earlier.2 A positive culture requires pregnancy-appropriate treatment and follow-up through a clinician. Antibiotic selection depends on the organism, susceptibility, pregnancy stage, allergies, and safety.
Urine protein on a dipstick or routine urinalysis does not diagnose preeclampsia. Suspected preeclampsia requires blood pressure, symptoms, gestational age, and clinician-selected blood and urine testing. Likewise, urine glucose does not replace blood-based gestational diabetes testing.
| Infection or immunity question | Who is commonly tested and when | Common initial laboratory approach | Follow-up and direct-access limitation |
|---|---|---|---|
| Syphilis | Universal testing as early as possible in each pregnancy; repeat testing later according to current ACOG guidance, exposure, risk, local epidemiology, or law | Treponemal and nontreponemal testing in an accepted algorithm | Discordant or reactive results require prompt confirmation, staging, treatment, partner services, and fetal/newborn planning4 |
| HIV | All pregnant patients early; repeat in the third trimester when risk is increased; rapid testing at labor or delivery when status is unknown | Fourth-generation HIV antigen/antibody test, with supplemental confirmation and nucleic-acid testing when reactive | A reactive screen is preliminary and needs urgent confirmatory care and treatment planning57 |
| Hepatitis B | HBsAg at the first prenatal visit of every pregnancy, even if previously tested; delivery testing when status is unknown or risk is ongoing | Hepatitis B surface antigen, generally with confirmatory testing when reactive | Positive results require additional maternal evaluation and a documented newborn vaccine and immune-globulin plan6 |
| Hepatitis C | Universal screening during each pregnancy, except in rare settings with extremely low prevalence under CDC criteria | HCV antibody with reflex or follow-up HCV RNA testing | A reactive antibody does not prove current infection; RNA testing and specialist follow-up are needed9 |
| Chlamydia | All pregnant patients younger than 25 and patients 25 or older with increased risk; repeat in the third trimester for younger or at-risk patients | Nucleic-acid amplification test from the recommended specimen | Positive results require pregnancy-appropriate treatment, partner management, test of cure, and retesting7 |
| Gonorrhea | All pregnant patients younger than 25 and patients 25 or older with increased risk; repeat when risk persists | Nucleic-acid amplification test from the recommended specimen | Positive results require treatment, partner management, and retesting7 |
| Rubella immunity | Commonly assessed early when reliable immunity documentation is not available | Rubella IgG immunity testing | Nonimmune patients need exposure counseling and postpartum vaccination planning; MMR is a live vaccine and is not given during pregnancy19 |
| Varicella immunity | Tested when history or documentation is uncertain and the result would change management | Varicella-zoster virus IgG | A susceptible pregnant patient with exposure requires prompt clinical assessment; varicella vaccine is contraindicated during pregnancy and is generally addressed postpartum19 |
| Group B streptococcus | Vaginal-rectal screening late in each pregnancy, commonly during the 36th or 37th week | Culture of a properly collected vaginal-rectal swab | Result must be available to the delivery team for intrapartum management; an early urine culture or blood test does not replace the late-pregnancy swab18 |
| Tuberculosis | Risk-based rather than universal | TB blood test or skin test selected by the clinician | Positive screening requires evaluation for active disease, including clinical assessment and sometimes imaging |
| HSV, CMV, toxoplasmosis, parvovirus B19, or broad TORCH panels | Not routine universal blood screening for all asymptomatic pregnancies; testing is driven by symptoms, exposure, ultrasound findings, or specific history | Pathogen-specific serology, molecular testing, or other clinician-selected tests | Timing, prior immunity, cross-reactivity, false positives, and fetal implications make indiscriminate self-ordering difficult to interpret; routine HSV-2 serologic screening in asymptomatic pregnancy is not recommended by CDC7 |
A negative infection test is a snapshot. New exposure after testing can change status. A positive or indeterminate result may require a different confirmatory method, treatment, repeat timing, and newborn precautions. These are clinical-care decisions, not merely laboratory interpretation questions.
The USPSTF recommends screening for gestational diabetes at 24 weeks or later, and screening in the United States commonly occurs before 28 weeks.8 Practices use more than one accepted pathway:
The preparation instructions are not interchangeable. Eating when a fasting test was ordered, fasting unnecessarily before a nonfasting challenge, vomiting the glucose drink, completing the draw at the wrong time, or being acutely ill can make the result difficult to use.
A screening result above the cutoff is not automatically a diagnosis. Conversely, a normal early fasting glucose or A1C does not replace the standard later gestational diabetes pathway. Early testing may be used to look for previously unrecognized diabetes or in other selected circumstances, but the prenatal clinician should determine what the result changes.
For a broader explanation of TSH, free T4, free T3, antibodies, assay interference, and thyroid-result patterns, see the thyroid blood tests guide.
Pregnancy alters thyroid physiology. hCG can lower TSH early in pregnancy, estrogen increases thyroid-binding proteins, and assay performance varies. The American Thyroid Association published updated 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum care.21
TSH and free T4 may be especially relevant for patients with known thyroid disease, thyroid medication use, prior thyroid surgery or radioactive iodine, thyroid antibodies, goiter, autoimmune disease, symptoms, infertility history, prior pregnancy complications, or other risk factors. The test choice and follow-up interval should be established by the prenatal or endocrine clinician.
Interpretation should use the laboratory method and pregnancy-appropriate reference information whenever available. A nonpregnant TSH range, a self-defined “optimal” target, or isolated free T3 testing should not be used to adjust thyroid medication during pregnancy. Medication changes can affect both maternal and fetal health and require clinician oversight.
Hemoglobinopathies include structural hemoglobin variants, such as hemoglobin S, and disorders of hemoglobin production, such as thalassemias. A CBC can show microcytosis or another clue, but it cannot identify every carrier. ACOG’s updated guidance supports universal hemoglobinopathy testing for people planning pregnancy or at the initial prenatal visit when prior results are unavailable.22
Testing may use hemoglobin electrophoresis, high-performance liquid chromatography, capillary methods, or molecular testing depending on the question. Recent transfusion can obscure results. If a patient is a carrier, partner testing and genetic counseling may be appropriate. A parental carrier result does not diagnose the fetus.
| Test or situation | Preparation or collection issue | Pregnancy-specific interpretation issue | When to contact the prenatal team |
|---|---|---|---|
| CBC | Usually no fasting; hydration and recent IV fluids can change concentration | Plasma-volume expansion may lower hemoglobin and hematocrit; WBC and platelets may shift | Significant anemia, low platelets, abnormal smear findings, symptoms, or a rapidly changing trend |
| Ferritin and iron studies | Iron supplements, meals, collection time, inflammation, and recent infusion can affect components | Ferritin may look normal or high during inflammation despite iron restriction | Anemia, low MCV, intolerance of iron, prior hemoglobinopathy, or unclear cause |
| hCG quantitative | No routine fasting; use the same laboratory when trends are being compared when practical | Expected ranges overlap widely; one number does not establish location or viability | Pain, bleeding, fainting, an unexpected trend, or a result that was ordered for an urgent concern |
| ABO/Rh and antibody screen | No fasting; report transfusion, prior pregnancies, antibodies, and Rh immune globulin | Passive anti-D after Rh immune globulin can affect results; a positive screen needs identification | Rh-negative status with bleeding or a procedure; any positive antibody screen |
| Urine culture | Midstream clean-catch technique and prompt transport reduce contamination | Mixed flora may reflect contamination; treatment thresholds and follow-up differ in pregnancy | Positive culture, urinary symptoms, fever, flank pain, or repeated contaminated specimens |
| Rubella or varicella IgG | No fasting; vaccination and infection history matter | Immunity assays do not evaluate an acute exposure by themselves | Nonimmune result, rash, exposure, or uncertainty about vaccination timing |
| HIV, HBV, HCV, syphilis | No routine fasting; early window periods and recent exposure matter | Reactive screens often require confirmatory testing; negative results may not exclude a very recent infection | Any reactive, indeterminate, discordant, or new-exposure result |
| Glucose challenge | Follow the exact nonfasting instructions used by the prenatal program | It is a screening test; thresholds are protocol-specific | Result above the program threshold, vomiting, mistimed draw, or acute illness |
| Oral glucose tolerance test | Fasting and timed blood draws are essential; activity, smoking, food, and illness may affect results | Diagnostic criteria depend on the selected one-step or two-step protocol | Any abnormal value or incomplete test |
| TSH and free T4 | Report thyroid medication, biotin-containing supplements, timing of dose, and recent illness; do not stop medication without instruction | hCG, binding-protein changes, assay method, gestational age, and treatment targets matter | Abnormal result, symptoms, known thyroid disease, or a contemplated medication change |
| Hemoglobinopathy evaluation | Recent transfusion can mask the patient’s native hemoglobin pattern | Pregnancy does not turn a carrier result into fetal diagnosis; partner and genetic context matter | Any variant, suspected thalassemia, or discordance with CBC indices |
| Prenatal serum or cfDNA screening | Correct gestational age, singleton versus multiple pregnancy, donor egg, vanishing twin, transplant history, and prior screening matter | Results are probabilities and may be nonreportable; placental DNA may not match fetal status in every case | High-risk, positive, no-call, discordant, or unexpected result before any major decision |
Always follow the instructions attached to the specific laboratory order. General preparation advice cannot override the selected method or prenatal program.
The following report is fictional and is designed to show how context changes interpretation. It is not a patient-specific schedule or diagnostic example.
| Result | Fictional value | Initial reading | What the prenatal team still needs to consider |
|---|---|---|---|
| ABO/Rh | A negative | The patient is Rh negative | Antibody status, prior Rh immune globulin, bleeding or procedures, and the pregnancy’s Rh-management plan |
| RBC antibody screen | Negative | No unexpected RBC antibodies detected at this time | Repeat testing may be part of the prenatal plan; a later sensitizing event can change management |
| Hemoglobin | 11.6 g/dL | Not markedly low in this fictional example | Symptoms, laboratory pregnancy ranges, prior values, diet, MCV, and later trend |
| MCV | 86 fL | Normocytic red cells | Does not rule out early iron depletion or every hemoglobinopathy |
| Platelets | 250 x 10^9/L | Within the laboratory’s reported interval | Trend and clinical context remain important |
| Urine culture | No growth | No bacteriuria detected in the submitted specimen | New urinary symptoms later require reassessment |
| Rubella IgG | Immune | Laboratory evidence of immunity | No MMR vaccination is needed during pregnancy; documentation should remain in the prenatal record |
| HBsAg, HCV antibody, HIV screen, syphilis screen | Nonreactive | No laboratory evidence detected by these screening tests at that time | Window periods, later exposure, repeat-testing recommendations, and local requirements |
The Rh-negative result is not an emergency, and the negative antibody screen is reassuring, but the patient still needs a clinician-managed Rh plan. The infection results are not lifetime guarantees. The CBC is interpreted with pregnancy and trend context rather than a nonpregnant “optimal” range.
| Result | Fictional value | Initial reading | Appropriate next step |
|---|---|---|---|
| One-hour glucose challenge | 148 mg/dL, flagged | Above this fictional program’s screening cutoff | It is not a diagnosis; complete the prenatal program’s diagnostic test under the exact preparation instructions |
| Hemoglobin | 10.3 g/dL | Anemia is possible | Review MCV, symptoms, diet, bleeding history, ferritin or other studies, and alternative causes |
| MCV | 78 fL | Microcytosis | Iron deficiency and hemoglobinopathy are among the possibilities; do not assume one cause from MCV alone |
| Repeat antibody screen | Negative | No antibody detected at this time | The prenatal clinician determines Rh immune globulin timing and any later repeat testing |
The key lesson is that a flagged glucose screen leads to a diagnostic pathway, not an immediate diagnosis. Likewise, a microcytic anemia pattern needs cause-focused evaluation before assuming that more iron is the only answer.
Direct-access testing can sometimes help a patient obtain a selected blood or urine result, verify a prior measurement, or prepare for a more informed appointment. It cannot replace:
A test can be technically available yet still be inappropriate to order outside care because the timing, specimen, confirmation, treatment, or fetal implications require immediate coordination.
Where available and legally permitted, selected direct-access tests may be useful when the patient has a clear question and a follow-up plan. Examples may include confirming a documented test was not completed, obtaining a CBC or ferritin result before a scheduled clinician discussion, or checking a clinician-requested thyroid marker when the ordering pathway has been coordinated.
Before ordering, ask:
Learn more in Direct-Access Lab Testing: How It Works and What to Expect.
Avoid using routine self-ordered testing to:
Repeat testing is useful when it answers a specific question. Examples include:
Repeating a test without knowing what result would change care can create anxiety and conflicting data. Use How to Read and Understand Lab Results to review reference intervals, trends, false positives, and confirmatory testing principles.
Contact the prenatal team promptly for a positive infection result, positive red-cell antibody screen, Rh-negative status with bleeding or trauma, markedly abnormal CBC, abnormal glucose pathway, concerning thyroid result, repeated contaminated urine cultures, or a prenatal genetic screen that is positive, high risk, discordant, or nonreportable.
Seek immediate medical care for severe or increasing vaginal bleeding; severe abdominal, pelvic, or shoulder pain; dizziness or fainting; severe headache; vision changes; chest pain; shortness of breath; seizure; fever with serious illness; fluid leakage; severe vomiting with inability to keep fluids down; or fetal movement that has stopped or slowed.20 Routine laboratory ordering is not the correct response to an emergency.
Related broad guides include Women’s Hormone Blood Tests, Nutrition, Vitamin, Mineral, and Micronutrient Testing, and Infectious Disease, Immunity, Vaccine, and Titer Testing.
These links are educational starting points, not a self-directed prenatal order set. Confirm the current product contents, specimen, preparation, availability, price, and turnaround information on the test page, and coordinate pregnancy-specific use with the prenatal team.
Important: Cell-free DNA/NIPS, chorionic villus sampling, amniocentesis, and the late-pregnancy vaginal-rectal group B strep swab are discussed for completeness but are not linked as routine self-directed products here. Their selection, timing, specimen collection, interpretation, and follow-up should be coordinated through prenatal care.
These are not a universal self-order list for pregnancy. Selection and timing should follow a defined clinical question.
The prenatal program must determine which one-step or two-step protocol, dose, cutoff, fasting status, and specimen timing apply. These tests are not interchangeable.
No panel automatically represents the correct prenatal schedule. Compare every component with the prenatal care plan, avoid duplicate testing, and verify current product contents, specimen requirements, preparation, availability, price, and turnaround information on the product page.
Where direct access is available, eligible patients may be able to review selected laboratory options and current pricing online, complete the applicable ordering process, use a participating collection location, and receive results through an online account. Results can then support a more informed conversation with an obstetrician, maternal-fetal medicine specialist, nurse practitioner, certified nurse-midwife, primary-care clinician, endocrinologist, genetic counselor, or other qualified professional.
Pregnancy-specific use remains limited by timing, state availability, specimen requirements, test-method differences, and the need for immediate follow-up. Review The Complete Guide to Lab Tests and Blood Work, How to Read and Understand Lab Results, and Direct-Access Lab Testing: How It Works and What to Expect before using a direct-access result.
Common early testing includes a CBC, ABO blood type and Rh factor, RBC antibody screen, rubella immunity, hepatitis B, hepatitis C, HIV, and syphilis screening. A urine culture is also commonly performed, and varicella, chlamydia, gonorrhea, hemoglobinopathy, thyroid, glucose, or other tests may be added according to records, age, history, symptoms, and risk.
It answers a different question. A qualitative urine or blood test reports whether hCG is detected. A quantitative blood test reports a concentration and may contribute to a clinician-directed early-pregnancy evaluation. One numerical result cannot prove viability or locate the pregnancy.
No. hCG values overlap widely. Gestational dating relies on menstrual and conception information when reliable and, importantly, prenatal ultrasound. hCG may provide supporting information in selected early-pregnancy situations but should not be used as an exact pregnancy clock.
ABO and Rh type describe red-cell antigens. The antibody screen looks for maternal antibodies that could react with fetal red cells. Rh-negative status does not mean an antibody is present, and Rh-positive patients can still have non-D antibodies.
No. The antibody must be identified, and its clinical significance depends on the antigen, strength or titer, prior history, and fetal antigen status. The prenatal team determines whether specialized monitoring is needed.
No. Urinalysis may miss asymptomatic bacteriuria, and contamination can complicate interpretation. Urine culture is the established screening method during pregnancy.
Gestational diabetes screening is commonly performed between 24 and 28 weeks. Earlier testing may be used for a different question, such as previously unrecognized diabetes, when the prenatal team identifies a reason.
It depends on the test. The one-hour glucose challenge used for screening in many practices is generally nonfasting. A diagnostic oral glucose tolerance test requires fasting and timed samples. Follow the exact instructions from the prenatal program.
Not necessarily. Thyroid testing is especially relevant for known thyroid disease, medication use, symptoms, thyroid antibodies, autoimmune disease, goiter, prior thyroid treatment, or other risk factors. The prenatal clinician should determine the test and interval.
A CBC is commonly used, while ferritin or broader iron studies are often targeted to anemia, low red-cell indices, symptoms, diet, blood loss, prior deficiency, or treatment monitoring. Guidance and practice vary for asymptomatic universal iron-deficiency screening.
Screening estimates the chance of selected conditions. Cell-free DNA, serum screening, and AFP are screening tests. CVS and amniocentesis are diagnostic procedures for the conditions tested. A positive screen should be evaluated with counseling and, when chosen, diagnostic confirmation.
Prenatal cfDNA should be selected through prenatal care because correct gestational age, pregnancy type, prior screening, ultrasound findings, what the panel covers, and the plan for positive or nonreportable results all matter. The FDA emphasizes that NIPS is screening, not diagnosis.
A negative early test does not protect against later exposure. Repeat testing may be recommended because of current ACOG guidance, personal risk, a new partner or exposure, a prior positive result, local epidemiology, state requirements, or presentation late to care.
No. Panel components differ, may duplicate completed testing, and may omit gestational-age-specific screening, ultrasound, swab collection, or clinician-only procedures. A panel should be compared with the prenatal plan component by component.
Severe bleeding, severe abdominal or pelvic pain, shoulder pain, fainting, severe headache, vision changes, chest pain, trouble breathing, fluid leakage, seizure, serious fever, or reduced fetal movement requires immediate clinical assessment. Do not wait for a routine lab result.
Pregnancy blood tests and prenatal urine tests provide important information about maternal blood counts, blood type and Rh factor, red-cell antibodies, urine bacteria, immunity, infections, glucose regulation, thyroid function, iron status, and inherited blood conditions. Prenatal genetic blood tests can estimate probability, but they do not replace diagnostic procedures.
The value of each result depends on why it was ordered, the gestational window, the exact method, pregnancy-specific reference information, prior results, symptoms, medications, and the follow-up plan. Direct-access testing may support selected questions, but it cannot replace prenatal visits, ultrasound, blood-pressure assessment, fetal monitoring, genetic counseling, treatment, or urgent care.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
